MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

87.43 0.18

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

85.58

Максимум

88.9

Ключови измерители
By Trading Economics
Приходи	5.4M -48M
Продажби	6M 57M
Марж на печалбата	-82.974
Служители	414
EBITDA	5.1M -43M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+57.98% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-492M 5.9B
Предишно отваряне	87.25
Предишно затваряне	87.43

Настроения в новините

By Acuity

26%

74%

84 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.04.2026 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14.04.2026 г., 23:24 ч. UTC

Горещи акции

Stocks to Watch: Gloo, Broadcom, GitLab

14.04.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14.04.2026 г., 21:32 ч. UTC

Значими двигатели на пазара

GitLab Shares Rise on Expanded Google Cloud Collaboration

14.04.2026 г., 23:54 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Technical Correction -- Market Talk

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14.04.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14.04.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14.04.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14.04.2026 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14.04.2026 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14.04.2026 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14.04.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

14.04.2026 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14.04.2026 г., 20:32 ч. UTC

Горещи акции

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14.04.2026 г., 19:59 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14.04.2026 г., 19:38 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 19:27 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14.04.2026 г., 19:21 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14.04.2026 г., 19:09 ч. UTC

Придобивния, сливания и поглъщания

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14.04.2026 г., 18:30 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.04.2026 г., 18:30 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

57.98% нагоре

12-месечна прогноза

Среден 137.14 USD 57.98%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

84 / 348 Класиране в Здравеопазване

Финанси

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.